Research Article
Variation in Assessing Renal Allograft Rejection: A National Assessment of Nephrology Practice
Table 2
Summary of CPV results (N=525).
| | Variable (n) | Results |
| | CPV Domain | | | Overall (525) | 46.7±16.0 |
| | Physical (525) | 77.7±22.4 | | Workup (525) | 47.8±33.3 | | Diagnosis-Treatment (525) | 34.2±24.8 |
| | Low-value tests, # (525) | 0.9±1.4 | | Low-value tests, $ (525) | $229±$567 |
| | Specific Items | | | Biopsy of renal allograft | | | Active rejection, clinical (173) | 47.4% | | Active rejection, subclinical (173) | 10.9% | | Other, non-rejection (173) | 36.0% | | Primary diagnosis | | | Active rejection, clinical (173) | 57.7% | | Active rejection, subclinical (173) | 10.3% | | Other, non-rejection (173) | 79.4% | | Secondary diagnosis | 46.2% |
| | IV steroids for active rejection (350) | 26.3% | | Continue mycophenolate mofetil dose (520) | 61.5% | | Tacrolimus Dose in CNI Toxicity | | | Continue current dose (297) | 42.4% | | Decrease dose (109) | 78.9% | | Increase dose (119) | 21.9% | | Follow-up visit (525) | 24.2% | | Continue medications (525) | 53.7% | | Referral to vascular surgeon when appropriate (66) | 72.7% |
|
|
